Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares stood at 1.34 million during the last session, with the company’s beta value hitting -1.26. At the close of trading, the stock’s price was $8.47, to imply an increase of 0.95% or $0.08 in intraday trading. The CADL share’s 52-week high remains $14.60, putting it -72.37% down since that peak but still an impressive 84.18% since price per share fell to its 52-week low of $1.34.
Analysts have given a consensus recommendation of Buy for Candel Therapeutics Inc (CADL), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CADL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.23.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
After registering a 0.95% upside in the last session, Candel Therapeutics Inc (CADL) has traded red over the past five days. The 5-day price performance for the stock is -19.15%, and 30.63% over 30 days. With these gigs, the year-to-date price performance is -2.48%.
Candel Therapeutics Inc (CADL) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -46.75% for the past 5-year period. While 2025 is set for a -4.53% return in earnings, projections for the next 5 years are at 0.88% annually.
CADL Dividends
Candel Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
The next major institution holding the largest number of shares is BLACKROCK INC. with 0.82 million shares, or about 2.819% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.1 million.
We also have Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Candel Therapeutics Inc (CADL) shares. Going by data provided on Dec 31, 2024, Fidelity Select Portfolios – Biotechnology holds roughly 3.92 shares. This is just over 12.06% of the total shares, with a market valuation of $33.15 million. Data from the same date shows that the other fund manager holds a little less at 555.0, or 1.71% of the shares, all valued at about 4.7 million.
